You are currently using an unsupported browser which could affect the appearance and functionality of this website. Please consider upgrading to the latest version or using alternatives such as Mozilla Firefox, Google Chrome or Microsoft Edge.

Targeted Therapies for the Management of Ovarian Cancer (Scientific Impact Paper No. 12)


In the UK each year, ovarian cancer is diagnosed in over 6500 women and causes approximately 4400 deaths. Many women present with advanced disease with little prospect of cure. The 5-year survival rate for advanced ovarian cancer between 2005 and 2009 was 43%.

The current standard of care consists of the combination of radical surgery and platinum-based chemotherapy. Although key advances in surgical and chemotherapeutic strategies have led to small improvements in outcome, there still remains a significant risk of recurrence and resistance to therapy and a need to improve current treatment options.

This paper discusses the various available treatment options and areas where further research is needed.

COVID disclaimer

This Scientific Impact Paper was developed prior to the emergence of the COVID-19 coronavirus.

Version history

This is the second edition of this Scientific Impact Paper, which was originally published in 2008 under the same title.

Please note that the Scientific Advisory Committee regularly assesses the need to update. Further information on this review is available on request.

Developer declaration of interests

Available on request

This page was last reviewed 06 September 2013.